Abstract To address evidence gaps on the management of complications related to mesh in pelvic floor surgery, we created an evidence-based algorithm that includes defining evidence gaps. We utilized the Delphi method within a panel of surgeons treating mesh complications to define a treatment strategy. The first round provided a list of clinically based postulates that informed a review expanding postulates to recommendations and included grading of the quality of evidence. A second round informed the final algorithm. While the quality of the available evidence is low, it provides a framework for planning diagnosis and management of mesh-related complications.
Introduction
Female pelvic reconstructive surgery has significant failure rates even when performed by experienced surgeons. The use of mesh to enhance results began with the sacral colpopexy (SCP) followed by mid-urethral slings (MUS). The success of MUS spawned the transvaginal mesh (TVM) procedures for pelvic organ prolapse (POP). The use of TVM for POP has declined significantly, while MUS and SCP continue to be performed in large numbers.
The reality of surgery is that complications occur even with appropriate indication and excellent technique. The use of mesh adds potential complications to those that already attend reconstructive surgery. Recent systematic reviews indicate that some of these complications are not successfully resolved, leaving women to suffer long-term impact on quality of life. Surgeons increasingly use lighter weight macroporous polypropylene, but the impact on the incidence and management of mesh complications is unclear.
The Scottish Independent Review of the use, safety, and efficacy of transvaginal mesh implants in the treatment of stress urinary incontinence and pelvic organ prolapse in women, published in March of 2017, is the most recent systematic review on the topic. 1 Its commission was based on an Act of Parliament motivated by public concern that complications related to TVM were inadequately acknowledged and treated. It advocates improved education for physicians, patientcentred care using multi-disciplinary teams, and improved informed consent. Towards balancing the benefits and risks of the use of mesh in pelvic reconstructive surgery, the report highlights the importance of improved long-term data, better data aggregation, and crucially, the importance of developing pathways for the treatment of complications. 1 The objective of this study is to develop a treatment algorithm for the management of mesh complications using a structured communication process with a panel informed by systematic analysis of the available literature. The goal for the algorithm is to establish a scheme that will inform physicians treating mesh complications and define gaps in the literature for future investigations.
Methods
The investigation began with the formation of a panel of surgeons with expertise in performing mesh procedures and treating mesh complications. Panel members had clinical experience that included a significant portion of clinical practice dedicated to mesh complications. All authors have published on mesh use and have served on panels and workshops focused on the management of mesh complications.
We applied the Delphi method to define a strategy for managing mesh complications that included diagnostic and therapeutic considerations. The panel was asked a series of questions about the management of different types of mesh complications. The first round provided an initial list of clinically based postulates grounded on experience and knowledge of the literature (Table 1 ).
The investigators then did a systematic literature review for each postulate. Postulates were revised and expanded into recommendations based on the systematic reviews. These recommendations were arranged into a management algorithm that was subsequently subjected to a second round of questions of the expert panel. The final algorithm was based on the consensus of the panel.
The impetus for this study was the paucity of information available to inform counselling of patients suffering from mesh-related complications. While our motivation was improving the experience of patients with mesh complications, the study did not lend itself to the involvement of patients who were not directly involved in the study planning or implementation. Because there was no patient involvement in this study, it is exempt from research ethics board review.
The postulates that defined algorithm branches (Table 1 ) provided the questions for literature reviews. Each postulate had a separate literature search using set criteria that included using PubMed as the search engine and encompassing all English publications. Each article was graded in terms of the study's risk of bias and level of evidence, using the Canadian Task Force on Health Examination Evaluation of Evidence criteria (Table 2) . 2 The references for all articles were also added to the search. All articles were assessed for pertinence to the postulate and were entered into the database. The postulates were then revised based on the level of evidence, and recommendations were graded using the Canadian Task Force on Health Examination Classification of Recommendations criteria (Table 2) . 3 For many postulates, the level of evidence was low, with a high potential for bias because they were based primarily on descriptive studies, case reports, and a few observational studies. Consequently, our conclusions about the needs for future research are tentative. This level of evidence made strict adherence to preferred reporting items for systematic reviews and metaanalyses (PRISMA) guidelines challenging.
Results

Stratification of mesh-related complications
The use of mesh in reconstructive pelvic surgery includes different indications and approaches, and complications vary based on these parameters. 4 Several retrospective studies noted that, compared with MUS, mesh complications after POP surgery were significantly more likely to include exposure and vaginal symptoms, and an Accordion Classification severity grade 4 complication. [4] [5] [6] [7] Because the morbidity and treatment of MUS complications vary significantly from procedures using mesh for POP, initial treatment planning should be stratified by indications (grade B: limited evidence; moderate-high bias risk). [4] [5] [6] [7] [8] [9] Moreover, within surgeries for POP, the complications associated with TVM and SCP also differ. Symptoms following TVM for POP include dyspareunia and recurrent POP, while vaginal discharge secondary to mesh exposure is more common following SCP. 5 The literature also describes different treatment protocols and outcomes for procedures addressing complications of TVM for POP and SCP. 4, 9 Consequently, treatment planning of complications related to mesh procedures should be stratified based on indication and approach, with distinct approaches for MUS, TVM for POP procedures, and SCP (grade B: limited evidence; moderate-high bias risk). 4, 5, 9, 10 Complications following MUS include exposure, pain, sexual dysfunction and functional failure, manifesting as recurrent stress urinary incontinence (SUI) or voiding dysfunction. Studies show that patients with mesh exposure present with different symptoms from those without exposure, including less pain, more bleeding, and vaginal discharge. 4, 10 Management of MUS complications should be stratified by presenting symptoms (grade B: limited evidence; moderate-high bias risk). Similarly, different presentations and management approaches for mesh-related complications with POP surgery should be stratified based on presenting symptoms: exposure, pain, sexual dysfunction, and recurrent POP (grade B: limited evidence with moderate-high bias risk).
4,10,11
Management of complications following MUS
There is prodigious evidence for the effectiveness of MUS, with no significant difference in short-or medium-term efficacy and growing evidence on the long-term efficacy for both the transobturator (TO-MUS) and retropubic (RP-MUS) approaches. 12, 13 There is no difference in the prevalence of mesh exposure at 1-2%. 12, 14 Postoperative complications are low, although TO-MUS has less bladder injury compared with RP-MUS (0.6% versus 4.5%, RR 0.53; 95% CI 0.43-0.65), vascular injury, and voiding dysfunction (RR 0.53; 95% CI 0.43-0.65). 12 There is a higher incidence of pelvic pain with TO-MUS. Suprapubic pain is less common after TO-MUS (RR, 0.29; 95% CI 0.11-0.78) but is rare overall. Groin pain is not rare, and higher with TO-MUS compared with RP-MUS (6.4% versus 1.3%; RR 4.12, 95% CI 2.71-6.27). 12 Based on this, The Scottish Independent Review recommended the use of RP-MUS over TO-MUS (grade E: good evidence with low risk of bias).
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Functional failure after MUS MUS can fail because of persistent SUI or postoperative voiding dysfunction. Voiding dysfunction after MUS may be transient and respond to bladder drainage and voiding trials, with 2% requiring sling revision by 6 weeks. 15, 16 Several retrospective studies support prompt treatment with sling loosening in the early post-operative period when conservative management fails (grade B: fair evidence; moderate bias risk). [16] [17] [18] [19] The exact window for sling release or loosening is probably less than 3 weeks. 18 The majority of patients will be relieved of voiding dysfunction and remain continent. 16 For voiding dysfunction that presents later, once tissue ingrowth is complete, sling division has a success rate of~40%, with better results in younger patients (OR = 3.2), and those without OAB (OR = 3.1). 20 Preoperative urodynamics may offer diagnostic value in this late cohort (grade I: weak evidence; high bias risk). 21 For both populations, MUS division provides better results than partial or complete sling removal (grade B: limited evidence; low bias risk). 20 Recurrent SUI occurs in 40-50% after delayed MUS division or release. 22, 23 Persistent SUI after MUS is uncommon. A secondary analysis of two RCTs revealed 6% retreatment within 5 years. 24 Despite this low rate of recurrence, repeat MUS appears to have a lower success rate of 61%. 25 Although this qualifies as complicated SUI, usually considered an indication for urodynamics, urodynamic parameters do not appear to predict recurrent MUS outcome (grade D: limited evidence; moderate-high bias risk). 26 However, this low cure rate may be improved by defining the anatomical basis of failure using dynamic ultrasound to guide therapy (grade C: conflicting data, moderate-high bias risk). 26, 27 There is insufficient evidence to support surgical over nonsurgical management of recurrent SUI (grade I: limited evidence; low bias risk). 28 While periurethral injections are often recommended for failed slings, there is inadequate evidence to support them for this indication (grade I: weak evidence; moderate bias risk). 27 Repeat MUS may have better results than sling plication (grade B: limited evidence; low-moderate bias risk). 27, 28 There is also insufficient evidence to support pubovaginal fascial sling or colposuspension over MUS (grade I: limited evidence; moderate-high bias risk). 27 For repeat MUS, retropubic MUS may have better results than transobturator MUS (grade B: limited evidence; low bias risk). 28 Mesh exposure after MUS Exposure of mesh following MUS has a prevalence of 2%. 12, 14 It can present with concurrent vaginal, groin, leg or abdominal pain. 4, 29, 30 There is evidence to support a less invasive approach to patients with mesh exposure without concurrent pain, while those with mesh exposure and pain should be managed like patients presenting with pain (grade B: limited evidence; moderate bias risk). 4, 31, 32 Office treatment of exposure, whether it involves hormone therapy, trimming, or both, is rarely successful (grade C: conflicting evidence; high bias risk). [4] [5] [6] 33, 34 A bothersome isolated vaginal exposure should be treated with surgical excision of mesh to the point of tissue ingrowth and epithelial closure (grade B: limited evidence; moderate-high bias risk). 4, 33 When exposure includes the lower urinary tract, the exposed mesh within the urethra and bladder needs to be approached though the lower urinary tract. Transurethral and endoscopic techniques, including those utilizing laparoscopy and holmium laser, offer less invasive approaches than the alternative: cystotomy or urethrotomy with mesh excision and closure. [35] [36] [37] [38] [39] Transurethral or endoscopic treatment may be successful and is less invasive, although up to a third of patients treated may have persistent exposed mesh requiring another procedure. 38 Cystotomy or urethrotomy with excision and closure appears to be more effective, but with greater morbidity; consequently, the minimally invasive approaches may be appropriate as initial treatment (grade C: inconsistent evidence; high bias risk).
33,40
Pain after MUS The prevalence of pain has been reported as high as 15% for TO-MUS and 3% for RP-MUS. 12, 41 Overall rates of groin pain are higher in the TO-MUS group (6.4 versus 1.3%; RR 4.12, 95% CI 2.71-6.27; 18 trials, 3221 women; moderate quality evidence), whereas suprapubic pain was lower for TO-MUS (0.8 versus 2.9%; RR 0.29, 95% CI 0.11-0.78). 12 Pelvic pain associated with MUS has several aetiologies that warrant different management. Pain can be due to mesh contracture and resultant tethering of muscle in the upper thighs. 42 This is most common after TO-MUS, and usually responds to division of the vaginal portion of the MUS (grade B: limited evidence; moderate bias risk). 42, 43 There is limited evidence that complete removal of the vaginal wall portion of the sling provides better pain relief than partial removal, but at the expense of more complications. (grade C: conflicting evidence; moderate-high bias risk) 4, 33, 42, [44] [45] [46] For example, vaginal excision of an MUS has a recurrent SUI rate of 36-47%, with higher rates when more of the sling is removed. 4, 47 This creates tension between avoiding persistent pain with a minimalist approach and creating new symptoms with more aggressive removal. Persistent pain usually includes a component of pelvic floor spasm. Consequently, all patients complaining of pain should pursue pelvic floor physiotherapy both preand postoperatively (grade B: limited evidence; moderatehigh bias risk). 45, 48 Rarely, persistent pain can result from entrapment of the obturator nerve when a TO-MUS or RP-MUS has been used. Similarly, a chronic inflammatory response can cause pain with sling arms. Excision of the thigh portion of the sling should be reserved for patients with diagnostic evidence of nerve entrapment or chronic infection as it does not consistently impact symptoms and is not without morbidity (grade C: limited conflicting evidence; high bias risk). 49, 50 MRI and EMG are not useful diagnostic tests, although improvement in pain with injection of local anaesthetic supports complete excision. 50 Sexual dysfunction after MUS Sexual dysfunction after MUS usually relates to new onset dyspareunia or partner complaints of discomfort during sexual relations (hispareunia). 11, 51 Hispareunia, is generally due to mesh exposure and is resolved by successful partial excision of exposed mesh (grade B: limited evidence; moderate-high bias risk). 52 Dyspareunia associated with vaginal pain may be related to concurrent vaginal or groin pain, and may be successfully treated with complete excision of the vaginal portion of mesh (grade I: limited evidence; high bias risk). 11 However, postoperative dyspareunia following MUS generally has a component of pelvic floor muscle hypertonia, recommending pelvic floor physiotherapy both pre-and postoperatively (grade B: limited evidence; moderate-high bias risk).
45,48
Management of complications following TVM for POP
Mesh-related complications following TVM for POP procedures present with similar symptoms to MUS, including exposure, pain, and sexual dysfunction, as well as recurrent POP and urogenital and rectovaginal fistula. 31 The larger volume of mesh used in POP procedures has implications for treatment, including a higher frequency of mesh-related complications after POP procedures and increased opportunity for intra-operative complications during treatment. There seems to be a dose-response relationship between the amount of mesh used and subsequent complications. 10, 53 Moreover, treatment, including surgical treatment, often fails to relieve all symptoms, and successful treatment can require multiple surgeries in up to 15% of cases. 6, [54] [55] [56] This is a basis for different approaches to mesh-related complications following TVM and SCP. 4, [9] [10] [11] Further diagnostic testing may be indicated for some patients. For example, a complaint of pain warrants a workup for aetiologies of pelvic pain unrelated to mesh. Similarly, patients with lower urinary tract symptoms warrant cystoscopy. 4, 45 Some advocate preoperative ultrasound or MRI to locate mesh in the vaginal wall. 45 While the studies of ultrasound are limited, it appears to be the best imaging modality for locating mesh, and is more accurate than clinical exam. 57 Nevertheless, there is no compelling evidence to support intra-operative ultrasound at this time. In summary, perioperative workup may include cystoscopy, proctoscopy, colonoscopy, and ultrasound, although no universal recommendation exists (grade I: insufficient evidence; moderate-high bias risk)
Mesh exposure after TVM for POP Compared with SCP, the prevalence of exposure is markedly higher for TVM for POP -as high as 8-20% in the first year after surgery compared with 3-4% for SCP. [58] [59] [60] [61] A population-based study reflects a lower reoperation rate for exposure of 3%. 10 These studies probably underreport exposure as recent long-term data show increasing incidence for many years after the initial surgery. 4, 62, 63 The ongoing risk of exposure highlights the need for management options that balance efficacy with low morbidity. For those patients with mesh exposure that are asymptomatic, no treatment is indicated (grade D: limited evidence; moderate bias risk). 64 Women with mesh exposure and symptoms that include pelvic pain or dyspareunia should be managed based on the symptom of pain that seems to require more aggressive treatment. 11, 65 Office management of mesh exposure, whether it includes estrogen therapy, trimming, or both, has a very low morbidity, but is also ineffective in relieving exposures. (grade C: conflicting evidence; high bias risk). 4, 5, 33, 60 For exposures from TVM, partial excision, beginning with mobilization of epithelial edges, excision of eroded mesh to edges with tissue ingrowth, and epithelial closure, offers a minimally invasive approach. [31] [32] [33] 55, 60 Other authors recommend complete extirpation, in which the epithelium is dissected off the underlying mesh to the pelvic sidewall and all mesh within the vaginal wall is removed, as a better way to prevent recurrent exposure. 66, 67 When partial excision was compared with complete extirpation, there was no statistically significant difference in intraoperative or postoperative complications or need for reoperation, although the study had low power. 4 This suggests that partial excision may provide relief of symptoms related to exposure with a less invasive approach than full extirpation (grade C: conflicting evidence; moderate bias risk).
The recurrence rate for POP after extirpation is reported as 5.6-11.4%. 47, 67 The study with the lower rate used concurrent native tissue repairs, which were not utilized in the study with the recurrence rate of 11.4%. A number of authors recommend a concurrent native tissue repair when removing mesh for exposure 4, 67, 68 (grade B: fair evidence; low bias risk), and against additional mesh (grade D: limited evidence; moderate bias risk).
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Exposures that involve the lower urinary tract require more radical surgery. As opposed to MUS, endoscopic treatment of POP mesh in the urethra and bladder generally is insufficient. Cystotomy or urethrotomy with excision and closure may be more effective and can usually be accomplished through a vaginal approach (grade B: limited evidence; moderate-high bias risk). 33 Patients treated for rectovaginal fistula had a 90% cure rate, but with a mean of 4.4 surgeries and a 40% diversion rate. 69 In fact, persistence of symptoms and multiple surgeries are recurrent themes for mesh exposure after TVM for POP. 6, 54 Pelvic pain after TVM for POP Pelvic pain following a TVM for POP repair has several potential aetiologies with different management, but because pain usually includes hypertonia of the pelvic floor muscles, all patients should pursue pelvic floor PT pre-and postoperatively (grade B: limited evidence; moderate-high bias risk). 45, 48 Pain can be due to contracture of the mesh and resultant tethering of the upper thighs, especially following procedures that include mesh arms piercing the obturator membrane. 42 Pelvic pain, including groin pain, warrants division and complete removal of the vaginal mesh (grade B: limited evidence; moderate-high bias risk). 11, 65 The rate of residual pain is reported at 22-50%. 54, 70, 71 Persistent pain can result from entrapment of the obturator nerve with transobturator arms and pudendal neuralgia with sacrospinous ligament (SSL) arms (grade I: limited evidence; moderate-high bias risk). 43 A chronic inflammatory response can also cause vaginal pain. Nevertheless, excision of mesh outside the vaginal wall is not without morbidity, and should be reserved for patients with diagnostic evidence of nerve entrapment or chronic infection (grade I: limited evidence; moderate bias risk). 45, 50 Sexual dysfunction after TVM for POP Sexual dysfunction following TVM for POP can relate to dyspareunia, hispareunia, and loss of vaginal tissue and volume due to contracture and scarring. 11, 51 Hispareunia usually relates to irritation from mesh exposure, best treated with trimming of exposed mesh and epithelial closure (grade I: limited evidence; moderate-high bias risk). 52 In the scenario of dyspareunia due to mesh contracture, removal of the vaginal wall portion of the mesh may be appropriate (grade I: limited evidence; moderate-high bias risk).
11 Dyspareunia can also relate to pelvic floor hypertonia, and patients with dyspareunia should pursue pelvic floor PT (grade B: limited evidence; moderate-high bias risk). 48 Consider pudendal neuralgia for persistent dyspareunia with SSL mesh arms (grade I: limited evidence; moderate-high bias risk). 43 For those women who have lost vaginal volume or patency due to scarring, reconstructing the vaginal wall may be more successful after mesh removal (grade I: limited evidence; moderate-high bias risk).
Management of complications related to SCP
Mesh exposure after SCP Mesh exposure is the most common mesh complication after an SCP, with an incidence of 3-6% at 1-2 years, and an ongoing long-term cumulative risk. [61] [62] [63] 72, 73 Vaginal pain is less common, and low back pain due to osteomyelitis or discitis is much rarer. 61, 63, 74, 75 Mesh exposures after SCP differ from TVM for POP surgeries in terms of the location, presenting symptoms, and the potential for complications. 63 Vaginal discharge and spotting are most common, although some women are asymptomatic. 72 The principal of pursuing the minimal effective intervention to minimize complications pertains, especially given the reality that surgical management often requires multiple surgeries, is not always successful, and has a potential for major morbidity of 19% when laparotomy is required. 63, 72, 73 Asymptomatic women may not need intervention (grade I: no evidence). Conservative office therapy, including trimming and/or estrogen is not successful (grade D: limited evidence; moderate-high bias risk). 4, 72 Partial excision of eroded mesh with a partial colpocleisis via a vaginal approach is the recommended initial approach (grade B: good evidence; low-moderate bias risk). 4, 6, 63, 73, 77 Partial colpocleisis is minimally invasive, with low morbidity and a cure rate of 50%, although it is unsuccessful as a secondary procedure. 63, 72, 76 Recurrent mesh exposures are better managed with complete resection via laparotomy or laparoscopy, although this approach has higher blood loss and higher morbidity (grade B: fair evidence; low-moderate bias risk). 63, 72, 76 Mesh exposure into the bladder, urethra or bowel has the potential for significant morbidity. Cystotomy or urethrotomy, excision and closure seem to be more effective than endoscopic treatment (grade I: limited evidence; moderate-high bias risk). 63, 77, 78 Laparotomy and complete removal of mesh is recommended for exposure into the colon or rectum, and may require a diverting ostomy (grade I: limited evidence; high bias risk).
69
Pain after SCP Vaginal pain after SCP in the absence of mesh exposure is rare, but may respond to complete excision by laparotomy (grade I: limited evidence; high bias risk). 79 In women with exposure that presents with concurrent pain, especially back pain, sacral osteomyelitis and discitis should be considered. 61, 74, 75, 80 MRI is the preferred imaging modality (grade B: fair evidence; low-moderate bias risk). 81 The first line of treatment is prolonged antibiotics directed at Staphylococcus and Streptococcus, present in 50% of cases (grade B: limited evidence; moderate bias risk). 74, 82 Actinomyces is a frequently reported pathogen for which the choice of antibiotic and length of treatment is not well defined. 72 Patients who do not respond require orthopaedic debridement (grade B: limited evidence; moderate bias risk). 75, 77 Sexual dysfunction after SCP Following SCP, most women report improvements in pelvic floor symptoms that previously interfered with sexual function. 83 There is a paucity of evidence on sexual dysfunction.
Discussion
The development of RP-MUS revolutionized the treatment of SUI. It also induced an explosion of TVM procedures for POP. Their development focused on achieving the anatomical outcomes of SCP with the advantages of a vaginal approach. These products were marketed with inadequate safety studies because their regulatory approval was based on the FDA 510 mechanism, eliminating the requirement for safety and efficacy data for Class II devices with prerequisite device. Recent systematic reviews conclude that MUS, especially RP-MUS, have a favourable benefit-to-risk ratio when compared with the standard colposuspension. Conversely, the use of TVM for POP repairs does not improve outcomes and significantly increases complications.
1 Moreover, the Scottish Independent Review noted that adverse events are inconsistently diagnosed and inadequately treated. They concluded: '[there is a need to] develop appropriate pathways to meet clinical needs and also for the management of those suffering complications.' 1 While incomplete, there is evidence to inform the optimal management of mesh complications. We have organized this evidence to construct a treatment algorithm for management of mesh-related complications following surgery for UI (Figure 1 ) and POP (Figure 2) , including diagnostic testing and treatment. Initial treatment forks are based on the indication for the initial surgery, whether for incontinence or POP, with subsequent stratification by surgical approach for POP procedures. To eliminate symptoms and simultaneously minimize new complications, the amount of mesh removed varies according to the presenting symptoms. Indications of pain or visceral involvement warrant more aggressive removal of mesh, which is associated with new complications, including recurrent UI or POP.
Conclusion
Not only is the available evidence low in quality, there are also large gaps in existing knowledge. Specific research gaps are indicated (Table 3) . We believe that future research in this area should prioritize these topics. This will allow our specialty to define more robust evidence-based recommendations about optimal treatment of mesh complications.
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